Meeting category
Date(s)
11 Nov 2015 - 12 Nov 2015
Program Language
English
Location
Vancouver, Canada
Meeting type
Live Meeting
Organizer
Platinum Level Support
Sponsor logos
Gilead - Creating Possible

International Hepatitis Cure & Eradication Meeting 2015

Related Enduring Materials

Enduring Materials

Day 1 - Wednesday, 11 November 2015

-
The Toronto Declaration - Where are we now?
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
Session 1: Hepatitis Vaccines: What does the Future hold? -
Hepatitis C Vaccines: Are we making progress?
Christopher Walker
Christopher M. Walker, PhD
The Research Institute at Nationwide Children’s Hospital, Ohio
A hepatitis C Vaccine: How do we prove it works?
Kim Page
Kimberly Page
UCSF School of Medicine, USA
Hepatitis B Vaccine: Optimizing coverage and efficacy
Alex Vorsters, PhD
University of Antwerp, Belgium
Panel Discussion
Session 2: Testing Strategies for at Risk Populations -
Point-of-care (POC) testing in Hepatitis B and C
Scott Bowden
Scott Bowden, PhD
The Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
Baby Boomer Screening in the U.S: Delivering on the promise thus far?
John Ward, MD
Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States
New tools for testing and monitoring Hepatitis B and C
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Victorian Infectious Diseases Reference Laboratory
Session 3: Optimizing Treatment in Hepatitis B and C -
New Treatment Strategies for Hepatitis B
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Maximizing SVR with current HCV therapy
Alnoor Ramji
Alnoor Ramji, MD, FRCP
University Of British Columbia, Canada
New Treatment in HCV: Is there need for more therapies?
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada

Day 2 - Thursday, 12 November 2015

Session 4: Access to Care: A Global Perspective -
Hepatitis C treatment in resource-limited countries
Gamal Esmat, MD
Gamal Esmat, MD
Cairo University, Egypt
Hepatitis C treatment
Manal Hamdy El-Sayed, MD, PhD
Ain Shams University, Egypt
Rational pricing and the role of generics
Raymond Schinazi, PhD, DSc
Emory University Center for AIDS Research (CFAR), United States
Panel Discussion
Session 5: How to prioritize HCV Treatment -
Perspective from health economics
David Rein
David Rein, PhD
NORC at the University of Chicago, USA
Perspective from Civil Society
Tracy Swan
Tracy Swan
Treatment Action Group, USA
Perspective from Payers
Mel Krajden
Mel Krajden, MD, FRCPC
BC Centre for Disease Control, Canada
Bonnie Henry, MD, MPH, FRCPC,
Bonnie Henry, MD, MPH, FRCPC
Ministry of Health of British Colombia, Canada
Perspective from Medical Community
Overview

Dear colleague,

A very succesful 2nd edition of the International Hepatitis Cure & Eradication Meeting 2015 has taken place in at the Marriott Pinnacle Vancouver Downtown Hotel in Vancouver, Canada, 11 - 12 November 2015.

This workshop has brought together global inter-disciplinary experts to provide a framework for how science can inform public policy to achieve the goal of global hepatitis eradication.

We would like to thank all faculty members, the participants and the sponsors for contributing to this meeting and therefore making this meeting a success!

Kind regards,

The Organizing Committee

Support
Platinum Level
Contributor